Effect of intravenous Ascorbic Acid on reducing ferritin in Hemodialysis Patients

Effect of short-term and low amount of intravenous Ascorbic Acid on reducing ferritin in Hemodialysis Patients without increasing the start dosage of erythropoietin: crossed over double blind randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138904263325N3

Enrollment

Registered

2010-09-14

Start date

2009-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease. End-stage renal disease

Interventions

Intervention 1: 500mg of intravenous vitamin C (IVAA) along with each dialysis session at the first week of each month for three months (total 1500mg/3month). Intervention 2: control group did not rec

Treatment - Drugs

500mg of intravenous vitamin C (IVAA) along with each dialysis session at the first week of each month for three months (total 1500mg/3month)

control group did not receive any intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: receiving hemodialysis therapy for at least 6 months, administered EPO for 6 months or longer at a dose of 80-360 U/kg/wk or greater, rolling 3-month average Hb level of 11.0 g/dL or less (110 g/L), ferritin level greater than 500 ng/Ml, transferrin saturation (TSAT) of 20% or less and administered maintenance intravenous iron (25-100 mg/week) Exclusion criteria: bone marrow malignancy, myelodysplastic syndrome, evidence of chronic infection, hemochromatosis, hemoglobinopathies, evidence of significant bleeding (decrease in Hb level = 2 g/dL during the past 3 months, mean corpuscular volume greater than 100 fL, biointact parathyroid hormone (bio-PTH) level greater than 500 pg/mL (ng/L)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ferritin. Timepoint: begining of each phase and after 3 months. Method of measurement: laboratory techniques.;Hemoglobin. Timepoint: beginning of each phase and each months (0-1-2-3). Method of measurement: laboratory techniques.	—

Secondary

Measure	Time frame
Serum Iron. Timepoint: at the beginning of study and after 3 months. Method of measurement: laboratory techniques.;TIBC. Timepoint: at the beginning of study and after 3 months. Method of measurement: laboratory techniques.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Mirzamohammadi

Zanjan University of Medical Sciences

fateme_mm@yahoo.co.uk+98 24 1426 6934

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026